Bioavailability and bioequivalence requirements; BCS classification MCQs With Answer

Introduction

Bioavailability and bioequivalence are cornerstone concepts in regulatory sciences and essential for M.Pharm students preparing for careers in drug development and regulatory affairs. This blog provides a concise, focused set of multiple-choice questions on bioavailability, bioequivalence study requirements, and the Biopharmaceutics Classification System (BCS). Questions cover regulatory expectations (including Indian CDSCO practice), key pharmacokinetic metrics (AUC, Cmax, Tmax), study designs, biowaiver criteria, dissolution testing (f2), excipient effects, and special cases such as highly variable and narrow therapeutic index drugs. Use these MCQs to solidify conceptual understanding and to prepare for exams and practical regulatory tasks.

Q1. What is the definition of absolute bioavailability?

• The fraction of an orally administered dose that reaches the systemic circulation compared to the same dose given intravenously
• The rate at which a drug is eliminated from the body
• The total amount of drug excreted unchanged in urine
• The time taken to reach maximum plasma concentration

Correct Answer: The fraction of an orally administered dose that reaches the systemic circulation compared to the same dose given intravenously

Q2. Which two pharmacokinetic parameters are primary endpoints in bioequivalence studies?

• AUC (area under the curve) and Cmax (maximum plasma concentration)
• Tmax and half-life (t1/2)
• Volume of distribution and clearance
• Bioavailability and absorption rate constant (ka)

Correct Answer: AUC (area under the curve) and Cmax (maximum plasma concentration)

Q3. What is the usual regulatory acceptance range for the 90% confidence interval of the geometric mean ratio for AUC and Cmax in BE studies?

• 80.00% to 125.00%
• 70.00% to 143.00%
• 90.00% to 111.11%
• 60.00% to 140.00%

Correct Answer: 80.00% to 125.00%

Q4. Which description correctly defines a BCS Class I drug?

• High solubility, high permeability
• Low solubility, high permeability
• High solubility, low permeability
• Low solubility, low permeability

Correct Answer: High solubility, high permeability

Q5. Which BCS class is characterized by low solubility and high permeability?

• Class II
• Class I
• Class III
• Class IV

Correct Answer: Class II

Q6. Which BCS class has high solubility but low permeability?

• Class III
• Class II
• Class I
• Class IV

Correct Answer: Class III

Q7. Which BCS class represents drugs with both low solubility and low permeability?

• Class IV
• Class I
• Class II
• Class III

Correct Answer: Class IV

Q8. According to commonly used regulatory solubility criteria, when is a drug considered “highly soluble”?

• If the highest single therapeutic dose is soluble in 250 mL or less of aqueous media over the pH range 1.0–7.5
• If it dissolves 85% within 15 minutes in water
• If the log P is less than 1.0 in octanol-water
• If the drug is completely absorbed in humans

Correct Answer: If the highest single therapeutic dose is soluble in 250 mL or less of aqueous media over the pH range 1.0–7.5

Q9. How is “high permeability” commonly defined for the purposes of BCS classification?

• Extent of absorption is generally ≥85% of the administered dose
• The drug has a log P greater than 3.0
• The compound is a substrate for P-glycoprotein
• The drug shows rapid dissolution in pH 6.8 buffer

Correct Answer: Extent of absorption is generally ≥85% of the administered dose

Q10. For which BCS classes are regulatory biowaivers most commonly granted (subject to additional dissolution and excipient criteria)?

• Class I and, under specific conditions, Class III
• Class II and Class IV
• Only Class I worldwide without any conditions
• All classes if in vitro dissolution is similar

Correct Answer: Class I and, under specific conditions, Class III

Q11. What is the typical in vivo study design for a single-dose bioequivalence study of an immediate-release oral dosage form?

• Randomized, two-period, two-sequence crossover in healthy volunteers (fasting)
• Parallel design in patients with multiple dosing for 14 days
• Open-label single arm in healthy volunteers with no cross-over
• Randomized triple-blind, four-period design in patients

Correct Answer: Randomized, two-period, two-sequence crossover in healthy volunteers (fasting)

Q12. What is the similarity factor (f2) threshold indicating two dissolution profiles are similar?

• f2 value between 50 and 100
• f2 value below 30
• f2 value greater than 150
• f2 value equal to zero

Correct Answer: f2 value between 50 and 100

Q13. Which statement best describes the impact of formulation excipients on BCS Class III drugs?

• Excipients can significantly influence absorption of Class III drugs, so strict excipient control is required for biowaivers
• Excipients never affect Class III drugs and therefore are not regulated
• Only colorants affect Class III drug absorption
• Excipients only matter for parenteral formulations, not oral Class III drugs

Correct Answer: Excipients can significantly influence absorption of Class III drugs, so strict excipient control is required for biowaivers

Q14. What does Cmax represent in pharmacokinetics?

• The maximum observed plasma concentration after drug administration
• The total plasma exposure over time
• The time taken for half the drug to be eliminated
• The clearance normalized to bioavailability

Correct Answer: The maximum observed plasma concentration after drug administration

Q15. What does Tmax indicate in a PK profile?

• The time to reach maximum plasma concentration (Cmax)
• The total exposure (AUC)
• The absolute bioavailability
• The volume of distribution at steady state

Correct Answer: The time to reach maximum plasma concentration (Cmax)

Q16. Which regulatory approach is typically used to address highly variable drugs (intra-subject CV >30%) in BE assessment?

• Reference-scaled average bioequivalence (RSABE) or widened limits with scaling
• Mandatory parallel design with smaller sample sizes
• Use of f2 dissolution testing instead of in vivo BE
• Automatic biowaiver without any in vivo testing

Correct Answer: Reference-scaled average bioequivalence (RSABE) or widened limits with scaling

Q17. How are narrow therapeutic index (NTI) drugs commonly treated in bioequivalence regulatory practice?

• They often require tighter BE acceptance limits (for example approximately 90–111% for AUC/Cmax) and careful study design
• They are exempt from BE studies
• They always receive a biowaiver regardless of BCS class
• They may be tested only using in vitro dissolution methods

Correct Answer: They often require tighter BE acceptance limits (for example approximately 90–111% for AUC/Cmax) and careful study design

Q18. When is a fed-state BE study required instead of a fasting study?

• When the reference product labeling instructs administration with food or food markedly affects the test product’s absorption
• Always; fed-state is the only acceptable condition
• Only when the drug is BCS Class I
• Fed studies are never required for oral immediate-release products

Correct Answer: When the reference product labeling instructs administration with food or food markedly affects the test product’s absorption

Q19. Which pharmacokinetic metric is most sensitive to changes in the rate of absorption?

• Cmax
• AUC
• Volume of distribution
• Renal clearance

Correct Answer: Cmax

Q20. Which authority in India is primarily responsible for regulation and approval of bioequivalence studies and generics?

• Central Drugs Standard Control Organization (CDSCO)
• Food Safety and Standards Authority of India (FSSAI)
• Indian Council of Medical Research (ICMR)
• Pharmacy Council of India (PCI)

Correct Answer: Central Drugs Standard Control Organization (CDSCO)

Download